Skip to content

Author

F. Alanyalı

We have 1 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Assessing the significance of CCNE1 overexpression in triple negative breast cancer.

CCNE1 overexpression characterises a clinically aggressive subset of breast cancers, particularly TNBC, and targeting mTORC1 may represent a promising therapeutic approach in CCNE1-high, TP53-mutated, and RB1-deficient tumours, supporting the clinical utility of CCNE1 in patient stratification and targeted therapy.

Nigar Pelin Makas, N. Belder, Özge Akbulut-Çalışkan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.